Compare GCTS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | NSPR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | GCTS | NSPR |
|---|---|---|
| Price | $1.40 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.50 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 119.6K | 101.5K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,893,000.00 | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | $1,205.88 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $0.90 | $1.59 |
| 52 Week High | $2.76 | $3.80 |
| Indicator | GCTS | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 48.80 |
| Support Level | $1.40 | $1.74 |
| Resistance Level | $1.49 | $2.00 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 59.52 | 53.85 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.